-
Original Article
-
Korean J Obstet Gynecol. 2005;48(6):1448-1455. Published online June 1, 2005.
- Clinical analysis of Paclitaxel and Platinum in Recurrent Carcinoma of the Uterine Cervix.
-
Seung Wook Jeon, Young Tak Ju, Ji Hyeon Kim, Ok Joo Ahn, Young Moon, Kwang Beom Lee, Jin Woo Shin, Jong Min Lee, Chan Yong Park
-
Department of Obstetrics and Gynecology, Gachon Medical School, Inchon, Korea. mjb307@hanmail.net
- Abstract
- OBJECTIVE
This study was performed to evaluate the efficacy and the toxicity of paclitaxel and platinum in patients with recurrent cervical carcinoma. METHODS: Twenty nine patients were treated with paclitaxel 135-175 mg/m2 and cisplatin 50-75 mg/m2 or carboplatin at AUC 5 every 3 weeks for a maximum of six courses from January 2001 to January 2004. RESULTS: A total 134 cycles with paclitaxel and platinum were administered. Ten patients (34.2%) achieved an objective response, including four complete responses (13.6%) and six partial responses (20.6%). Overall survival was 13.2 months, and the response and non-response group were 23.2 and 8.1 months, respectively (p=0.01). Clinical response according to recurrent site was significantly different (p=0.048) but, survival was not (p=0.22). Grade 3 or 4 granulocytopenia in 75.9% of patients was developed and one expired due to neutropenic sepsis after first cycle chemotherapy. CONCLUSION: The combination of paclitaxel and platinum seems relatively well tolerated and has 34.2% response rate in patients with recurrent cervical cancer. Further study for this combination chemotherapy and prognostic factor should be needed.
Keywords :Recurrent;Cervical cancer;Paclitaxel;Platinum
